Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Patrick R LawlerHongyan LiuClaudia FrankfurterLeif Erik LovblomYuliya LytvynDylan BurgerKevin D BurnsDavor BrincDavid Z I CherneyPublished in: Diabetes care (2021)